nach oben

Erschienen in:

01.04.2009 | Leitthema

Präkanzerosen und frühinvasive Karzinome

Nichtchirurgische Behandlung der Haut von Gesicht und Kopf

verfasst von: Prof. Dr. E. Haneke, Dermatologische Klinik Inselspital, Univ. Bern, Schweiz, Dept. Dermatol., Academisch Ziekenhuis, Univ. Gent, Belgien, Centro Dermatol., Instituto CUF, Porto, Portugal

Erschienen in: HNO | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Zusammenfassung

Chronische Sonnenlichtexposition mit ihrem hohen Ultraviolettanteil ist die Hauptursache der gängigen Präkanzerosen und Karzinome von Kopf und Hals. Dadurch kommt es zur Feldkanzerisierung mit häufig multiplen aktinischen Keratosen (AKs), Basalzellkarzinomen (BCCs) und Plattenepithelkarzinomen (SCCs). Die chirurgische Exzision, die Therapie mit den höchsten Heilungs- und niedrigsten Rezidivraten, stößt hier schnell an ihre Grenzen. Die Anwendung unspezifisch kaustischer Mittel kann oberflächliche Veränderungen beseitigen, jedoch sind die neueren Verfahren der lokalen Zytostase mit 5-Fluorouracil (5-FU), der photodynamischen Therapie mit 5-Aminolävulinsäure (ALA) bzw. ihrem Methylester (MeALA), der topischen Anwendung des Immunmodulators Imiquimod und des Zyklooxygenasehemmers Diclofenac deutlich wirksamer mit weitaus höherer Spezifität. Weitere Möglichkeiten sind intra- und peritumorale Injektionen von Zytostatika und Interferonen sowie neue krebsspezifische Mittel. Von herausragender Bedeutung ist die Prophylaxe des chronischen Lichtschadens.

Graham GF, Camacho F, Roseborough I et al (2005) Patients with solar keratosis, particularly of the trunk or lower extremities, are at high risk for skin cancer development. Clin Exp Dermatol 30:717–718PubMedCrossRef

Quaedvlieg PJF, Tirsi E, Thissen MRTM, Krekels GA (2006) Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 16:335–339PubMed

Morton C, Horn M, Leman J et al (2006) Comparison of topical methyl levulinate photodynamic with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol 142:729–735PubMedCrossRef

Smith S, Piacquadio D, Morhenn V et al (2003) Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol 2:629–635PubMed

Perrett CM, McGregor JM, Warwick J et al (2007) Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 156:320–328PubMedCrossRef

Loven K, Stein L, Furst K et al (2002) Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 24:990–1000PubMedCrossRef

Paolino D, Cosco D, Muzzalupo R et al (2008) Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharm 353:233–242PubMedCrossRef

Saif MW, Hashmi S, Mattison L et al (2006) Peripheral neuropathy exacerbation associated with topical 5-fluorouracil. Anticancer Drugs 17:1095–1098PubMedCrossRef

Kennedy JC, Pottier RH (1992) Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 14:275–292PubMedCrossRef

10.

Haneke E (2005) Photodynamic therapy for scarless removal of multiple facial precanceroses and superficial carcinomas. In Bosniak S, Cantisano-Zilkha M (eds) Minimally invasive techniques of oculofacial rejuvenation. Thieme, New York, Stuttgart 151–157

11.

Haneke E (2009) Photodynamic treatment. In Cantisano-Zilkha M, Haddad M (eds) Aesthetic Oculofacial Rejuvenation. Elsevier, New York (in press)

12.

Angell-Petersen E, Sorensen R, Warloe T et al (2006) Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol 126:265–271PubMedCrossRef

13.

Kalisiak MS, Rao J (2007) Photodynamic therapy for actinic keratoses. Dermatol Clin 25:15–23PubMedCrossRef

14.

Blume JE, Oseroff AR (2007) Aminolevulinic acid photodynamic therapy for skin cancers. Dermatol Clin 25:5–14PubMedCrossRef

15.

Touma D, Yaar M, Whitehead S et al (2004) A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 140:33–40PubMedCrossRef

16.

Christiansen K, Bjerring P, Troilius A (2007) 5-ALA for photodynamic photorejuvenation--optimization of treatment regime based on normal-skin fluorescence measurements. Lasers Surg Med 39:302–310PubMedCrossRef

17.

Ceburkov O, Gollnick H (2000) Photodynamic therapy in dermatology. Eur J Dermatol 10:568–575 (disc 576)PubMed

18.

Tull S, Nunley K, Sengelmann R (2008) Nonsurgical treatment modalities for primary cutaneous malignancies. Dermatol Surg 34:1–14CrossRef

19.

Braathen LR, Szeimies RM, Basset-Seguin N et al (2007) Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology 2005. J Am Acad Dermatol 56:125–143PubMedCrossRef

20.

Morton C, Campbell S, Gupta G et al (2006) Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 155:1029–1036PubMedCrossRef

21.

Kurwa HA, Yong-Gee SA, Seed PT et al (1999) A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 41:414–418PubMedCrossRef

22.

Morton CA, Whitehurst C, McColl JH et al (2001) Photodynamic therapy for large or multiple patches of Bowen’s disease and basal cell carcinoma. Arch Dermatol 137:319–324PubMed

23.

Morton CA (2007) Methyl aminolevulinate: actinic keratoses and Bowen’s disease. Dermatol Clin 25:81–87PubMedCrossRef

24.

Fritsch C, Goerz G, Ruzicka T (1998) Photodynamic therapy in dermatology. Arch Dermatol 134:207–214PubMedCrossRef

25.

Vinciullo C, Elliott T, Francis D et al (2005) Photodynamic therapy with topical methyl aminolaevulinate for ‚difficult-to-treat‘ basal cell carcinoma. Br J Dermatol 152:765–772PubMedCrossRef

26.

Horn M, Wolf P, Wulf HC et al (2003) Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol 149:1242–1249PubMedCrossRef

27.

MacCormack MA (2008) Photodynamic therapy in dermatology: An update on applications and outcomes. Sem Cut Med Surg 27:52–62CrossRef

28.

Rawlins J, Platt A, Gowda P (2006) Regression of BCC following immunosuppression withdrawal in a renal transplant recipient. Clin Exp Dermatol 31:717PubMedCrossRef

29.

Woodmansee C, Pillow J, Skinner RB Jr (2006) The role of topical immune response modifiers in skin cancer. Drugs 66:1657–1664PubMedCrossRef

30.

Schön MP, Schön M (2004) Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 9:291–298PubMedCrossRef

31.

Stanley MA (2002) Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27:571–577PubMedCrossRef

32.

Hadley G, Derry S, Moore RA (2006) Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 126:1251–1255PubMedCrossRef

33.

Stockfleth E, Christophers E, Benninghoff B et al (2004) Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 140:1542PubMedCrossRef

34.

Marks R, Gebauer K, Shumack S et al (2001) Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 44:807–813PubMedCrossRef

35.

Geisse JK, Rich P, Pandya A et al (2002) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 47:390–398PubMedCrossRef

36.

Shumack S, Robinson J, Kossard S et al (2002) Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 138:1165–1171PubMedCrossRef

37.

Ferreres JR, Macaya A, Jucgla A et al (2006) Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream. J Eur Acad Dermatol Venereol 20:877–878PubMedCrossRef

38.

Kossard S (2003) Treatment of large facial Bowen’s disease: case report. Clin Exp Dermatol 28(Suppl 1):13–15PubMedCrossRef

39.

Martin-Garcia RF (2005) Imiquimod: an effective alternative for the treatment of invasive cutaneous squamous cell carcinoma. Dermatol Surg 31:371–374PubMed

40.

Ahmed I, Berth-Jones J (2000) Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 143:843–845PubMedCrossRef

41.

Epstein E (2003) Extensive lentigo maligna clearing with topical imiquimod. Arch Dermatol 139:944–945PubMedCrossRef

42.

Chapman MS, Spencer SK, Brennick JB (2003) Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol 139:943–944PubMedCrossRef

43.

Ray CM, Kluk M, Grin CM et al (2005) Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int J Dermatol 44:428–434PubMedCrossRef

44.

Rosen T (2006) Limited extent AIDS-related cutaneous Kaposi’s sarcoma responsive to imiquimod 5% cream. Int J Dermatol 45:854–856PubMedCrossRef

45.

Schartz NEC et al (2008) Imiquimod 5% cream for treatment of HIV-negative Kaposi’s sarcoma skin lesions: a phase I to II, open-label trial in 17 patients. J Am Acad Dermatol 58:585–591

46.

Li VW, Li WW, Talcott KE, Zhai AW (2005) Imiquimod as an antiangiogenic agent. J Drugs Dermatol 4:708–717PubMed

47.

Nijisten T, Colpaert CG, Vermeulen PB et al (2004) Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol 151:837–845CrossRef

48.

Stashower ME (2006) Successful treatment of earlobe keloids with imiquimod after tangential shave excision. Dermatol Surg 32:380–386PubMed

49.

Ondo AL, Mings SM, Pestak RM, Shanler SD (2006) Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J Am Acad Dermatol 55:1104–1106CrossRef

50.

Fisher GH, Lang PG (2003) Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol 139:945–947PubMedCrossRef

51.

Goh MS (2006) Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream. Australas J Dermatol 47:186–188PubMedCrossRef

52.

Metcalf S, Crowson AN, Naylor M et al (2007) Imiquimod as an antiaging agent. J Am Acad Dermatol 56:422–425PubMedCrossRef

53.

Mendonça CO, Yates VM (2006) Permanent facial hypopigmentation following treatment with imiquimod cream. Clin Exp Dermatol 31:721PubMedCrossRef

54.

Thomsen LL, Topley P, Daly MG et al (2004) Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22:1799–1809PubMedCrossRef

55.

Schön M, Bong AB, Drewniok C et al (2003) Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95:1138–1149PubMed

56.

Masferrer JL, Leahy KM, Koki AT et al (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306–1311PubMed

57.

Huyke C, Laszczyk M, Scheffler A et al (2006) Behandlung aktinischer Keratosen mit Birkenkorkextrakt. J Dtsch Dermatol Ges 4:132–137PubMedCrossRef

58.

Bollag W (1970) Vitamin A and vitamin A acid in the prophylaxis and therapy of epithelial tumkors. Int J Vitam Nutr Res 40:299–314

59.

Peris K, Fargnoli MC, Chimenti S (1999) Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med 341:1767–1768PubMedCrossRef

60.

Calista D (2002) Topical 1% cidofovir for the treatment of basal cell carcinoma. Eur J Dermatol 12:562–564PubMed

61.

Gyurova MS, Stancheva MZ, Arnaudova MN et al (2006) Intralesional bleomycin as alternative therapy in the treatment of multiple basal cell carcinomas. Dermatol Online J 12:25PubMed

62.

Miller BH, Shavin JS, Cognetta A et al (1997) Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. J Am Acad Dermatol 36:72–77PubMedCrossRef

63.

Kraus S, Miller BH, Swinehart JM et al (1998) Intratumoral chemotherapy with fluorouracil/epinephrine injectable gel: a nonsurgical treatment of cutaneous squamous cell carcinoma. J Am Acad Dermatol 38:438–442PubMedCrossRef

64.

Morse LG, Kendrick C, Hooper D et al (2003) Treatment of squamous cell carcinoma with intralesional 5-fluorouracil. Dermatol Surg 29:1150–1153 (Diskussion 1153)PubMedCrossRef

65.

Aftergut K, Curry M, Cohen J (2005) Candida antigen in the treatment of basal cell carcinoma. Dermatol Surg 31:16–18PubMed

66.

High A, Zedan W (2005) Basal cell nevus syndrome. Curr Opin Oncol 17:160–166PubMedCrossRef

67.

Athar M, Li C, Tang X et al (2004) Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res 64:7545–7552PubMedCrossRef

68.

Taipale J, Chen JK, Cooper MK et al (2000) Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine. Nature 406:1005–1009PubMedCrossRef

69.

Mukherjee S, Frolova N, Sadlonova A et al (2006) Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther 5:674–683PubMedCrossRef

70.

So PL, Langston AW, Daniallinia N et al (2006) Long-term establishment, characterization and manipulation of cell lines from mouse basal cell carcinoma tumors. Exp Dermatol 15:742–750PubMedCrossRef

71.

Tabs S, Avci O (2004) Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol 14:96–102PubMed

72.

Miyazaki K, Saika S, Yamanaka O et al (2006) Treatment of eyelid epithelial neoplasm by targeting sonic hedgehog signaling: an experimental study. Jpn J Ophthalmol 50:305–311PubMedCrossRef

73.

Nishimaki H, Kasai K, Kozaki K et al (2004) A role of activated sonic hedgehog signaling for the cellular proliferation of oral squamous cell carcinoma cell line. Biochem Biophys Res Commun 314:313–320PubMedCrossRef

74.

Lizée G, Radvanyi LG, Overwijk WW, Hwu P (2006) Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin Cancer Res 12:2359s–2365sPubMedCrossRef

75.

Becker JC, Ugurel S, Bröcker E-B et al (2006) Neue Therapieansätze bei der Behandlung von Tumoren: Histondeacetylase-, Methyltransferase- und Proteasominhibitoren. J Dtsch Ges Dermatol 4:108–113CrossRef

76.

Langer CJ (2008) Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer 112:2635–2645PubMedCrossRef

77.

Francis SO, Mahlberg MJ, Johnson KR et al (2006) Melanoma chemoprevention. J Am Acad Dermatol 55:849–861PubMedCrossRef

Titel: Präkanzerosen und frühinvasive Karzinome
Nichtchirurgische Behandlung der Haut von Gesicht und Kopf
verfasst von: Prof. Dr. E. Haneke
Dermatologische Klinik Inselspital, Univ. Bern, Schweiz
Dept. Dermatol., Academisch Ziekenhuis, Univ. Gent, Belgien
Centro Dermatol., Instituto CUF, Porto, Portugal
Publikationsdatum: 01.04.2009
Verlag: Springer-Verlag
Erschienen in: HNO / Ausgabe 4/2009
Print ISSN: 0017-6192
Elektronische ISSN: 1433-0458
DOI: https://doi.org/10.1007/s00106-009-1892-5

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Präkanzerosen und frühinvasive Karzinome

Nichtchirurgische Behandlung der Haut von Gesicht und Kopf

Zusammenfassung

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update HNO

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Hauttumoren im Gesichtsbereich

Leitlinien: Antibiotikatherapie der Infektionen an Kopf und Hals

Histologie nach Tonsillektomie?

Lupus vulgaris als destruierender Nasen- und Gesichtstumor

Methicillinresistente Staphylokokken (MRSA, MRSE) im Nasen-, Nasennebenhöhlenbereich und Sputum

Protektion der Kochlea durch Vitamin C bei Lärmexposition

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update HNO